CN104684574B - 加压素-2受体的肽拮抗剂 - Google Patents

加压素-2受体的肽拮抗剂 Download PDF

Info

Publication number
CN104684574B
CN104684574B CN201380048382.9A CN201380048382A CN104684574B CN 104684574 B CN104684574 B CN 104684574B CN 201380048382 A CN201380048382 A CN 201380048382A CN 104684574 B CN104684574 B CN 104684574B
Authority
CN
China
Prior art keywords
protein
seq
amino acid
da2a
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380048382.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104684574A (zh
Inventor
N·吉勒斯
D·斯文特
L·昆顿
H·雷恩弗兰克
R·威兹戈尔
B·莫拉克
C·曼德里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Liege
Universitaet Regensburg
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Universite de Liege
Universitaet Regensburg
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Liege, Universitaet Regensburg, Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Universite de Liege
Publication of CN104684574A publication Critical patent/CN104684574A/zh
Application granted granted Critical
Publication of CN104684574B publication Critical patent/CN104684574B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201380048382.9A 2012-09-17 2013-09-17 加压素-2受体的肽拮抗剂 Active CN104684574B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306120.2A EP2708235A1 (en) 2012-09-17 2012-09-17 Peptide antagonists of the vasopressin-2 receptor
EP12306120.2 2012-09-17
PCT/IB2013/058615 WO2014041526A1 (en) 2012-09-17 2013-09-17 Peptide antagonists of the vasopressin-2 receptor

Publications (2)

Publication Number Publication Date
CN104684574A CN104684574A (zh) 2015-06-03
CN104684574B true CN104684574B (zh) 2018-08-31

Family

ID=46963639

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380048382.9A Active CN104684574B (zh) 2012-09-17 2013-09-17 加压素-2受体的肽拮抗剂

Country Status (14)

Country Link
US (1) US9631001B2 (enExample)
EP (2) EP2708235A1 (enExample)
JP (1) JP6392758B2 (enExample)
KR (1) KR102135954B1 (enExample)
CN (1) CN104684574B (enExample)
AU (1) AU2013316700B2 (enExample)
BR (1) BR112015005750B1 (enExample)
CA (1) CA2884361C (enExample)
DK (1) DK2895189T3 (enExample)
ES (1) ES2664747T3 (enExample)
MX (1) MX362664B (enExample)
NZ (1) NZ706202A (enExample)
RU (1) RU2015114320A (enExample)
WO (1) WO2014041526A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021528476A (ja) * 2018-06-28 2021-10-21 サルアクア ダイアグノスティックス， インコーポレイテッド ハプトグロビン関連タンパク質と関係する組成物および方法
EP3929209A1 (en) 2020-06-24 2021-12-29 Commissariat à l'Energie Atomique et aux Energies Alternatives Vasopressin-2 receptor antagonist peptides and uses thereof
CN115820734B (zh) * 2022-11-11 2024-12-13 北京希诺谷生物科技有限公司 中枢性尿崩症疾病模型犬的建立方法
CN116425888B (zh) * 2023-04-24 2024-11-05 徐州医科大学 一种多肽tat-v2r1c及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2007019267A1 (en) 2005-08-03 2007-02-15 Mineuet Therapeutics Ltd. MODULATING THE KV1.1 VOLTAGE-GATED POTASSIUM CHANNEL IN T-CELLS FOR REGULATING THE SYNTHESIS AND SECRETION OF TUMOR NECROSIS FACTOR α (TNF-α) AND TREATING HUMAN DISEASES OR INJURIES MEDIATED BY DETRIMENTALLY HIGH OR LOW LEVELS OF TNF-α
US8343760B2 (en) * 2008-06-05 2013-01-01 University Of Maryland, Baltimore p53 activator peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents;Punniyakoti T. et al;《Drug Discovery Today》;20101031;第15卷(第19-20期);第826-841页 *
Functional characterization of Kunitz-type protease inhibitor Pr-mulgins identified from New Guinean Pseudechis australis;Hidetoshi Inagaki et al;《Toxicon》;20111007;第59卷(第1期);第74-80页、摘要、图1 *

Also Published As

Publication number Publication date
CN104684574A (zh) 2015-06-03
AU2013316700B2 (en) 2017-10-12
EP2708235A1 (en) 2014-03-19
KR20150070172A (ko) 2015-06-24
JP6392758B2 (ja) 2018-09-19
BR112015005750A8 (pt) 2018-04-17
BR112015005750B1 (pt) 2022-08-16
WO2014041526A1 (en) 2014-03-20
EP2895189A1 (en) 2015-07-22
RU2015114320A (ru) 2016-11-10
DK2895189T3 (en) 2018-04-16
CA2884361A1 (en) 2014-03-20
MX362664B (es) 2019-01-31
BR112015005750A2 (pt) 2017-12-12
KR102135954B1 (ko) 2020-07-21
JP2016500001A (ja) 2016-01-07
EP2895189B1 (en) 2018-01-10
US9631001B2 (en) 2017-04-25
CA2884361C (en) 2022-03-22
AU2013316700A1 (en) 2015-04-09
US20150252086A1 (en) 2015-09-10
NZ706202A (en) 2018-06-29
MX2015003225A (es) 2015-11-16
ES2664747T3 (es) 2018-04-23

Similar Documents

Publication Publication Date Title
AU2011218243A1 (en) Fibronectin based scaffold domain proteins that bind IL-23
CN104684574B (zh) 加压素-2受体的肽拮抗剂
Rouget et al. Identification of a novel snake peptide toxin displaying high affinity and antagonist behaviour for the α2‐adrenoceptors
Reynaud et al. A venomics approach coupled to high-throughput toxin production strategies identifies the first venom-derived melanocortin receptor agonists
WO2011071280A9 (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
US7745569B2 (en) Amyloid specific binding peptides and detecting abeta peptide
EP3131922B1 (en) Polypeptides and uses thereof for reducing cd95-mediated cell motility
US9981005B2 (en) Methods for increasing DISC1 in a subject with schizophrenia or bipolar disorder by an antagonist inhibiting DISC1 binding to FBXW7
CN112534504A (zh) 配体和选择该配体的结合靶标的方法
US20030167129A1 (en) Binding compounds and methods for identifying binding compounds
EP3033094A1 (en) Map kinase p38 binding compounds
JP7617958B2 (ja) バソプレシン２受容体アンタゴニストペプチド及びその使用
US20030018438A1 (en) Binding compounds and methods for identifying binding compounds
WO2001070768A2 (en) Receptor-binding compounds and method for identifying them
US20240101604A1 (en) Selective mena binding peptides
Tzakoniati A Chemical Biology Approach to Understanding the Basis of Voltage-Gated Sodium Channel Modulation
Zhang et al. Structural basis of VAChT inhibition by spiroindolines and alkylsulfones
Mannes Discovery, Design and Synthesis of G Protein Peptidomimetics
Song et al. Expression and solution NMR study of multi-site phosphomimetic mutant BCL-2 protein
WO2011132938A2 (ko) Gpcr에 특이적으로 결합하는 gpcr-bpb
Young Turning Autophagy On and Off through the Class III PI-3 Kinase
Chen Novel pharmacology and distinct protein interactions of human alpha (1)-adrenergic receptor subtypes
Bower Molecular Determinants of Amylin Receptor Agonism
Stornaiuolo et al. Deorphanization of Adhesion GPCRs overexpressed in Glioblastoma
EP2226633A1 (en) Uses and methods for the identification of a cytoprotective compound involving gp130 or LIFRalpha

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant